MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Citations Over TimeTop 1% of 2012 papers
Abstract
Estrogen, progesterone, and HER2 receptor-negative triple-negative breast cancers encompass the most clinically challenging subtype for which targeted therapeutics are lacking. We find that triple-negative tumors exhibit elevated MYC expression, as well as altered expression of MYC regulatory genes, resulting in increased activity of the MYC pathway. In primary breast tumors, MYC signaling did not predict response to neoadjuvant chemotherapy but was associated with poor prognosis. We exploit the increased MYC expression found in triple-negative breast cancers by using a synthetic-lethal approach dependent on cyclin-dependent kinase (CDK) inhibition. CDK inhibition effectively induced tumor regression in triple-negative tumor xenografts. The proapoptotic BCL-2 family member BIM is up-regulated after CDK inhibition and contributes to this synthetic-lethal mechanism. These results indicate that aggressive breast tumors with elevated MYC are uniquely sensitive to CDK inhibitors.
Related Papers
- Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein.(1996)
- → Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy(2021)25 cited
- → Potential Clinical Uses of CDK Inhibitors: Lessons from Synthetic Lethality Screens(2015)14 cited
- → Inhibition of X-ray and Doxorubicin-induced Apoptosis by Butyrolactone I, a CDK-specific Inhibitor, in Human Tumor Cells(2000)4 cited
- → Cyclin-Dependent Kinase Inhibitor Gene(2020)1 cited